Korean J Pediatr Gastroenterol Nutr.  2000 Mar;3(1):56-62.

Serological and Histological Changes after Interferon Alfa Therapy in Children with Chronic Hepatitis B

Affiliations
  • 1Department of Pediatrics, Seoul National University Medical School, Seoul, Korea.
  • 2Department of Pathology, Seoul National University Medical School, Seoul, Korea.

Abstract

PURPOSE: The aim of this study was to evaluate the efficacy and histologic changes of interferon-alfa therapy on chronic hepatitis B virus infection in children.
PATIENTS AND METHODS
Thirty five children aged 3~16 years who were seropositive for HBV DNA, HBsAg and HBeAg were enrolled. Interferon-alfa 2a (3.4 MU/m(2)) were given for 6 months. Serologic markers of viral replication was evaluated 1 year after therapy. Post treatment liver biopsy was performed in 18 patients who showed serologic response.
RESULTS
Serum HBeAg and viral DNA became negative in 22 (63%) of treated children at 12 months after therapy. Serum aminotransferase levels normalized in all of the responders and HBsAg became negative in one responder. Horizontal transmission, serum aminotransferase levels more than twice normal, and active inflammation on liver biopsy were predictive factors for response to interferon therapy. Periportal piecemeal necrosis, lobular activity, portal inflammation, fibrosis, and total histologic activity index were reduced in responders.
CONCLUSION
In children with chronic hepatitis B, interferon alfa promotes loss of viral replication and improves aminotransferase. Serologic response is associated with improvement in hepatic histology.


MeSH Terms

Biopsy
Child*
DNA
DNA, Viral
Fibrosis
Hepatitis B e Antigens
Hepatitis B Surface Antigens
Hepatitis B, Chronic*
Hepatitis, Chronic*
Humans
Inflammation
Interferon-alpha*
Interferons*
Liver
Necrosis
DNA
DNA, Viral
Hepatitis B Surface Antigens
Hepatitis B e Antigens
Interferon-alpha
Interferons
Full Text Links
  • KJPGN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr